John S. Bomalaski

Polaris (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

43h-index6.9kcitations306works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(187), Cancer, Hypoxia, and Metabolism(76), Virus-based gene therapy research(64), Peptidase Inhibition and Analysis(61), Protein Degradation and Inhibitors(41)

Publications305 total

Supplementary Fig. 6 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Fig. 5 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Fig. 1 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Fig. 3 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Fig. 2 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Fig. 7 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Fig. 4 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Supplementary Tables 1-2 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment
2025Open Access
Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy
Blood·2025Open Access
Exploiting arginine auxotrophy in Philadelphia-chromosome positive acute lymphoblastic leukemia to deliver personalised metabolomic treatment
Blood·2025Open Access
Investigation of pegargiminase targeting the Fanconi anemia pathway and its role in DNA double-strand breaks induced by melphalan in uveal melanoma.
Journal of Clinical Oncology·2025
Supplementary Figure S3 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Supplementary Figure S1 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Supplementary Figure S5 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Supplementary Figure S4 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Supplementary Figure S2 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Data from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Supplementary Figure S5 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Figure 5 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
Supplementary Figure S1 from BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
2025Open Access
page 1 of 16Next →

Frequent Co-authors

Mike A. Clark(14), Peter W. Szlosarek(10), Mark Ensor(7), Frederick W. Holtsberg(7), Amanda Johnston(7), Nelofer Syed(5), Xiaoxing Feng(5), Francesco Izzo(4), M A Clark(4), Michael Sheaff(4), Tim Crook(4), Bor-Wen Wu(4), Chien‐Feng Li(4), Steven A. Curley(3), Giuseppe Castello(3), Gerardo Beneduce(3), Niramol Savaraj(3), Lynn G. Feun(3), Ghassan K. Abou‐Alfa(3), James J. Harding(3)